Articles: nausea.
-
Randomized Controlled Trial Multicenter Study
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the most frequent side effect. ⋯ Transient nausea and vomiting on treatment with liraglutide 3.0 mg was associated with greater weight loss, although symptoms appeared tolerable and did not attenuate quality-of-life improvements. Improved data collection methods on nausea are warranted.
-
Support Care Cancer · Apr 2014
Randomized Controlled Trial Multicenter StudyAprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.
Aprepitant, an oral neurokinin-1 receptor antagonist, has demonstrated improved control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of aprepitant in patients receiving highly emetogenic chemotherapy (HEC) in Asian countries. ⋯ The addition of aprepitant to standard antiemetic treatment regimens for Chinese patients undergoing HEC provided superior CINV prevention and was well tolerated.
-
Anesteziol Reanimatol · Jan 2014
Multicenter Study[Effect of preoperative infusion volume on frequency of intraoperative nausea and vomiting as complications of spinal anaesthesia in pregnant women during caesarian operation (pilot study)].
Purpose of the study was to define a prophylactic effect of different preload volumes on the rate of intraoperative nausea and vomiting (IONV) as a complication due to spinal anaesthesia (SA) during caesarian operation (SO) in parturient. Data for analysis was collected during clinical observational multi-center research included several medical centers. ⋯ The results suppose that preload is effective method of IONV prophylactics in parturient during SO under SA if only infused preload volumes do not break specially determined limits of effective interval. If preload volume value is out of this range then preinfusion may lead to increasing risk of IONV occurrence.
-
Support Care Cancer · Dec 2013
Multicenter StudyPalonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.
Recommendations for antiemetic prophylaxis supportive to radiotherapy and concomitant chemotherapy are not evidence-based. The purpose of this study was to evaluate the efficacy of the antiemetic regimen concurrent to fractionated radiotherapy and concomitant weekly cisplatin in two Danish departments of oncology. ⋯ The present study demonstrates that an antiemetic prophylaxis consisting of palonosetron and prednisolone is insufficient for the prevention of nausea and vomiting induced by radiotherapy and weekly cisplatin in patients treated for gynecological cancer. The addition of a neurokinin-1 receptor antagonist should be investigated in a randomized, double-blind study in this setting.
-
Multicenter Study Observational Study
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
We aimed to evaluate the efficacy of a new combination antiemetic therapy comprising aprepitant, granisetron, and dexamethasone in gastric cancer patients undergoing chemotherapy with cisplatin and S-1. ⋯ Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing treatment with cisplatin and S-1.